cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment
Ran Zuo, Yuchao He, Yulin Wu, Huien Yang, Yimeng Wang, Yu Wang, Wenchen Gong, Dongming Liu, Gengwei Huo, Liwei Chen, Yi Luo, Aomei Ling, Zhanyu Pan, Zhiyong Liu, Peng Chen, Hua Guo · 2026
Read cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment by Ran Zuo, Yuchao He, Yulin Wu, Huien Yang, Yimeng Wang, Yu Wang, Wenchen Gong, Dongming Liu, Gengwei Huo, Liwei Chen, Yi Luo, Aomei Ling, Zhanyu Pan, Zhiyong Liu, Peng Chen, Hua Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13572526.txt.
Description
Ran Zuo and colleagues found an enzyme that helps lung adenocarcinoma hide from immunotherapy, and a way to unmask it. Checkpoint drugs against PD-1 transformed lung cancer care, yet only a minority of patients respond, and resistance is common. Their 2026 study examined cytoplasmic phospholipase A2 alpha, an inflammation-linked enzyme overexpressed in tumours with poor prognosis.
Silencing the enzyme slowed cancer growth, but in immune-competent animals it also raised PD-L1, a shield against immune attack. Pairing silencing with anti-PD-1 therapy, however, drove killer T cells into tumours and suppressed growth synergistically. The authors propose the enzyme as a target to overcome PD-1 resistance, especially in patients with high enzyme levels and low baseline PD-L1.
Catalog record
| CREATOR | Ran Zuo, Yuchao He, Yulin Wu, Huien Yang, Yimeng Wang, Yu Wang, Wenchen Gong, Dongming Liu, Gengwei Huo, Liwei Chen, Yi Luo, Aomei Ling, Zhanyu Pan, Zhiyong Liu, Peng Chen, Hua Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |